Stem cell transplantation with reduced-intensity conditioning regimens: A review of ten years experience with new transplant concepts and new therapeutic agents

Leukemia

Volumn 20, Issue 10, 2006, Pages 1661-1672

  Barrett, A J ^a   Savani, B N ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMN 105; ANTIBODY; BMS 254825; BORTEZOMIB; BUSULFAN; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DASATINIB; FLUDARABINE; GANCICLOVIR; IMATINIB; INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; MELPHALAN; METHOTREXATE; MITOBRONITOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NILOTINIB; PENTOSTATIN; PEPTIDE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THIOTEPA; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MORTALITY; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; STEM CELL TRANSPLANTATION; VEIN OCCLUSION; WHOLE BODY RADIATION;

EID: 33750081766     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404334     Document Type: Article

References (126)

1. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511-533.
2. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292: 895-902.
3. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
4. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
5. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550-1558.
6. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLAmatched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplantation comorbidities. Blood 2004; 104: 961-968.
7. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
8. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829-3836.
9. Bishop MR. Allogeneic hematopoietic stem cell transplantation for metastatic breast cancer. Haematologica 2004; 89: 599-605.
10. Sykes M, Sachs DH. Bone marrow transplantation as a means of inducing tolerance. Semin Immunol 1990; 2: 401-417.
11. Sykes M, Sachs DH. Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol Today 1988; 9: 23-27.
12. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054.
13. Maris M, Storb R. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: A cellular therapeutic approach to hematologic and genetic diseases. Immunol Res 2003; 28: 13-24.
14. Slavin S, Morecki S, Weiss L, Shapira MY, Resnick I, Or R. Nonmyeloablative stem cell transplantation: Reduced-intensity conditioning for cancer immunotherapy - from bench to patient bedside. Semin Oncol 2004; 31: 4-21.
15. Spitzer TR. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist 2000; 5: 215-223.
16. McSweeney PA, Storb R. Mixed chimerism: Preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999; 5: 192-203.
17. Storb R, Yu C, Morecki S, McSweeney P. Mixed chimerism after transplantation of allogeneic hematopoietic cells. In: Thomas ED, Blume KG, Forman SJ (eds) Hematopoietic Cell Transplantation, 2nd edn Blackwell: Boston, 1999, pp 287-295.
18. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing highdose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
19. Sykes M, Spitzer TR. Non-myeloblative induction of mixed hematopoietic chimerism: Application to transplantation tolerance and hematologic malignancies in experimental and clinical studies. Cancer Treat Res 2002; 110: 79-99.
20. Slavin S. New strategies for bone marrow transplantation. Curr Opin Immunol 2000; 12: 542-551.
21. Slavin S. Biology of reduced intensity conditioning regimens. In: Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman P, Brenner MK (eds). Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd edn, Cambridge university press: Cambridge, UK, 2004, pp 121-135.
22. Carella AM, Beltrami G, Corsetti MT, Scalzulli P, Carella Jr AM, Musto P. A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity. Haematologica 2004; 89: 1534-1536.
23. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005; 366: 318-320.
24. Giralt S, Estey E, Albitar M, van BK, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versusleukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
25. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
26. Prigozhina TB, Gurevitch O, Zhu J, Slavin S. Permanent and specific transplantation tolerance induced by a nonmyeloablative treatment to a wide variety of allogeneic tissues: I. Induction of tolerance by a short course of total lymphoid irradiation and selective elimination of the donor-specific host lymphocytes. Transplantation 1997; 63: 1394-1399.
27. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S et al. Transplant-lite: Induction of graft-versusmalignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
28. Kassim AA, Jagasia MH, Vusirikala M, Dixon SL, Chinratanalab W, Morgan DS et al. Reduced intensity matched related (MRD) and matched unrelated (MUD) allogeneic stem cell transplantation (RIST) in adults with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): A single center experience. Biol Blood Marrow Transplant 2006; 12 (Suppl 1): 41 Ref Type: Abstract.
29. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reducedintensity conditioning: The role of dose intensity. Leukemia 2006; 20: 322-328.
30. Shaw BE, Russell NH, Devereux S, Das-Gupta E, Mackinnon S, Madrigal JA et al. The impact of donor factors on primary nonengraftment in recipients of reduced intensity conditioned transplants from unrelated donors. Haematologica 2005; 90: 1562-1569.
31. Blaise DP, Michel BJ, Faucher C, Mohty M, Bay JO, Bardoux VJ et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005; 104: 1931-1938.
32. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810-1814.
33. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616-1623.
34. Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG et al. Allogeneic stem cell transplantation after a fludarabine/ busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003; 82: 336-342.
35. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441-445.
36. Martino R, Caballero MD, Simon JA, Canals C, Solano C, Urbano-Ispizua A et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243-2245.
37. Bornhauser M, Kiehl M, Siegert W, Schetelig J, Hertenstein B, Martin H et al. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: A retrospective analysis. Br J Haematol 2001; 115: 119-124.
38. Dasgupta RK, Rule S, Johnson P, Davies J, Burnett A, Poynton C et al. Fludarabine phosphate and melphalan: A reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Bone Marrow Transplant 2006; 37: 455-461.
39. Delgado J, Thomson K, Russell N, Ewing J, Stewart W, Cook G et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: A British Society of Blood and Marrow Transplantation Study. Blood 2006; 107: 1724-1730.
40. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: Low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005; 35: 943-951.
41. Kroger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/ fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 698-708.
42. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865-3871.
43. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865-872.
44. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
45. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
46. Nieto Y, Patton N, Hawkins T, Spearing R, Bearman SI, Jones RB et al. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant 2006; 12: 217-225.
47. Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U et al. ematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3819-3829.
48. Stelljes M, Bornhauser M, Kroger M, Beyer J, Sauerland MC, Heinecke A et al. Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood 2005; 106: 3314-3321.
49. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 3535-3542.
50. Weisser M, Schleuning M, Ledderose G, Rolf B, Schnittger S, Schoch C et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant 2004; 34: 1083-1088.
51. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
52. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and post-grafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.
53. Sandmaier BM, Maris M, Maloney DG, Gooley TA, Stuart MJ, Hegenbart U et al. Low-dose total body irradiation (TBI) conditioning for hematopoietic cell transplants (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies: A five year experience. Blood 2003; 102 (Part 1): 78a-79a.
54. Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H et al. Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. Blood 2005; 105: 3035-3041.
55. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675-5687.
56. Khoury H, Adkins D, Brown R, Pence H, Vij R, Goodnough LT et al. Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen. Biol Blood Marrow Transplant 2001; 7: 352-358.
57. Claxton DF, Ehmann C, Rybka W. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2005; 130: 256-264.
58. Dean RM, Fowler DH, Wilson WH, Odom J, Steinberg SM, Chow C et al. Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11: 593-599.
59. Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: Impact of rituximab on immunomodulation and survival. Exp Hematol 2004; 32: 28-35.
60. Sloand E, Childs RW, Solomon S, Greene A, Young NS, Barrett AJ. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Bone Marrow Transplant 2003; 32: 897-901.
61. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21: 4407-4412.
62. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-3599.
63. Corradini P, Zallio F, Mariotti J, Farina L, Bregni M, Valagussa P et al. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol 2005; 23: 6690-6698.
64. Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6: 309-320.
65. Sandmaier BM, Storb R. Nonmyeloablative therapy and hematopoietic cell transplantation for hematologic disorders. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn Blackwell Publishing Ltd: Oxford, UK, 2004, pp 1164-1176.
66. Lee JH, Choi SJ, Lee JH, Kim SE, Park CJ, Chi HS et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan+cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005; 84: 321-330.
67. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
68. Koenecke C, Shaffer J, Alexander SI, Preffer F, Dombkowski D, Saidman SL et al. NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507. Exp Hematol 2003; 31: 911-923.
69. Spitzer TR. Haploidentical stem cell transplantation: The always present but overlooked donor. Hematology (Am Soc Hematol Educ Program) 2005, 390-395.
70. Spitzer TR, McAfee SL, Dey BR, Colby C, Hope J, Grossberg H et al. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 2003; 75: 1748-1751.
71. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
72. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
73. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-3213.
74. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
75. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674.
76. Gorin NC, Estey E, Jones RJ, Levitsky HI, Borrello I, Slavin S. New developments in the therapy of acute myelocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2000, 69-89.
77. Ringden O, Horowitz MM, Gale RP, Biggs JC, Gajewski J, Rimm AA et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993; 270: 57-60.
78. Baron F, Little MT, Storb R. Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev 2005; 19: 153-164.
79. Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG et al. Lymphohematopoietic graft-vs host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 1999; 5: 133-143.
80. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108-3114.
81. Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20: 4022-4031.
82. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy 2001; 3: 197-201.
83. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R et al. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121-3127.
84. Dodero A, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V et al. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: Graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol 2005; 33: 920-927.
85. Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404-406.
86. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reducedintensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387-9393.
87. Khouri IF, Albitar M, Saliba RM, Ippoliti C, Ma YC, Keating MJ et al. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: Decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant 2004; 33: 833-837.
88. Mineishi S, Kanda Y, Saito T, Nakai K, Makimoto A, Kami M et al. Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. Br J Haematol 2003; 121: 296-303.
89. Mineishi S, Schuening FG. Graf t-versus-host disease in minitransplant. Leuk Lymphoma 2004; 45: 1969-1980.
90. Diaz MA, Gonzalez-Vicent M, Gonzalez ME, Verdeguer A, Martinez A, Perez-Hurtado M et al. Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: A report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH). Bone Marrow Transplant 2005; 36: 781-785.
91. Schmitz N, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E et al. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica 2005; 90: 643-648.
92. Dreger P, Glass B, Seyfarth B, Humpe A, Claviez A, von NN et al. Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT. Bone Marrow Transplant 2000; 26: 1361-1362.
93. Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003; 17: 841-848.
94. Faulkner RD, Craddock C, Byrne JL, Mahendra P, Haynes AP, Prentice HG et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004; 103: 428-834.
95. Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 75-82.
96. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919-3924.
97. Ayuk F, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Sayer HG et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004; 18: 659-662.
98. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295-1303.
99. Shimazaki C, Fujii H, Yoshida T, Chou T, Nishimura M, Asaoku H et al. Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: Results from the Japan Myeloma Study Group. Int J Hematol 2005; 81: 342-348.
100. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005; 105: 4532-4539.
101. Nakagawa T, Kami M, Hori A, Kim SW, Murashige N, Hamaki T et al. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: Single institution experience with a minimum 1-year follow-up. Exp Hematol 2004; 32: 599-606.
102. Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P, Fernandez-Aviles F et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: A feasibility study. Haematologica 2003; 88: 555-560.
103. Arnold R, Massenkeil G, Bornhauser M, Ehninger G, Beelen DW, Fauser AA et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 2002; 16: 2423-2428.
104. Morris E, Mackinnon S. Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Transfus Apher Sci 2005; 32: 73-83.
105. Kanda Y, Komatsu Y, Akahane M, Kojima S, sano-Mori Y, Tada M et al. Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation 2005; 79: 821-827.
106. Bacigalupo A, Vitale V, Corvo R, Barra S, Lamparelli T, Gualandi F et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol 2000; 108: 99-104.
107. Barta A, Denes R, Masszi T, Remenyi P, Batai A, Torbagyi E et al. Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia. Acta Haematol 2001; 105: 64-70.
108. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969-2976.
109. Canals C, Martino R, Sureda A, Altes A, Briones J, Subira M et al. Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. Exp Hematol 2003; 31: 1039-1043.
110. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468-476.
111. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864.
112. Valcarcel D, Martino R, Sureda A, Canals C, Altes A, Briones J et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005; 74: 144-151.
113. Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reducedintensity conditioning compared with standard preparative regimens. Br J Haematol 2002; 119: 144-154.
114. Kim DH, Sohn SK, Baek JH, Kim JG, Lee JW, Min WS et al. Retrospective multicenter study of allogeneic peripheral blood stem cell transplantation followed by reduced-intensity conditioning or conventional myeloablative regimen. Acta Haematol 2005; 113: 220-227.
115. Solomon SR, Savani BN, Childs R, Montero A, Boss C, Read EJ et al. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome. Biol Blood Marrow Transplant 2005; 11: 619-626.
116. Deeg HJ. Transplant strategies for patients with myelodysplastic syndromes. Curr Opin Hematol 2006; 13: 61-66.
117. Slavin S, Morecki S, Weiss L, Shapira MY, Resnick I, Or R. Nonmyeloablative stem cell transplantation: Reduced-intensity conditioning for cancer immunotherapy - from bench to patient bedside. Semin Oncol 2004; 31: 4-21.
118. Sun K, Wilkins DE, Anver MR, Sayers TJ, Panoskaltsis-Mortari A, Blazar BR et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): Delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005; 106: 3293-3299.
119. Van Besien K. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev 2006, Feb 28 [Epub ahead of print].
120. Shah NP. Loss of response to imatinib: Mechanisms and management. Hematology (Am Soc Hematol Educ Program) 2005, 183-187.
121. Zenz T, Glatting G, Schlenk RF, Buchmann I, Dohner H, Reske SN et al. Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: Results of a phase I-II study. Haematologica 2006; 91: 285-286.
122. Karakhanova S, Munder M, Schneider M, Bonyhadi M, Ho AD, Goerner M. Highly efficient expansion of human CD4+CD25+ regulatory T cells for cellular immunotherapy in patients with graft-versus-host disease. J Immunother 2006; 29: 336-349.
123. Collin MP, Munster D, Clark G, Wang XN, Dickinson AM, Hart DN. In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: Implications for the control of graft-versus-host disease. Transplantation 2005; 79: 722-725.
124. Bondanza A, Valtolina V, Magnani Z, Ponzoni M, Fleischhauer K, Bonyhadi M et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 2005; 107: 1828-1836.
125. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R et al. Selective depletion of alloreactive donor lymphocytes: A novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005; 106: 1123-1129.
126. Barrett J. Fludarabine finds its significant other? Blood 2004; 104: 603-604.